Interleukin-4 and skin condition study
Part of Skin clinical trials.
This trial looks at a protein called Interleukin-4 in patients with Pityriasis Lichenoides Chronica (PLC), a skin condition with bumps or light-colored spots. The goal is to better understand the condition and find new ways to help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 8 years old or older
- You have been diagnosed with Pityriasis Lichenoides Chronica (a skin condition with raised bumps or light spots) that was confirmed by a skin biopsy
- You have not used any treatment for PLC in the last 3 months
- You do not have any other skin diseases
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with lichen planus (a rash that can affect skin, mouth, or genitals) to find markers in cells and blood that may help understand the disease. If you have a new diagnosis or a flare-up, and you are not on strong immune-suppressing medicine, you may be able to join.
This study looks at the immune cells in skin samples from people with psoriasis who are being treated with an anti-IL-23 biologic. The goal is to understand why some areas of skin do not improve or why flares happen, which may help improve treatments.
This study looks for clues in your skin and blood that could predict how well you'll respond to treatments for conditions like eczema, psoriasis, or lupus. It aims to help doctors choose the best therapy for you.
This study looks at the bacteria (microbiome) living on the skin in people with specific skin conditions, and in healthy volunteers. The results may help researchers understand what skin microbes have to do with these diseases.
This study looks at molecular (body-level) signatures in people with chronic inflammatory skin conditions. You may help researchers understand what drives inflammation, while receiving standard (already approved) systemic treatment through routine care.
This study looks at what affects the “path” (trajectory) of long-lasting inflammatory skin conditions. It may help researchers understand why symptoms change and how treatments or factors influence those changes.
Hear when a new Pityriasis Lichenoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.